三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
图表25诺华维格列汀销售情况(百万美元)
图表25诺华维格列汀销售情况(百万美元)
其它
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:171KB
图片尺寸:1759*1039
同报告图片
/
4
fCDlubTku70gfCDor7rljY7nu7TmoLzliJfmsYDplIDllK7mlLblhaXvvIjnmb7kuIfnvo7lhYPvvIkgfCBZb1kgfAp8IC0tLSB8IC0tLSB8IC0tLSB8CnwgMjAxN+W5tCB8IDEsMjAwIHwgLSB8CnwgMjAxOOW5tCB8IDEsMzAwIHwgLSB8CnwgMjAxOeW5tCB8IDEsMjAwIHwgLSB8CnwgMjAyMOW5tCB8IDEsMTAwIHwgLSB8CnwgMjAyMeW5tCB8IDEsMDAwIHwgLSB8CnwgMjAyMuW5tCB8IDgwMCB8IC0gfAoK6LWE5paZ5p2l5rqQ77ya6I2v6J6N5LqR77yM5Y2O5a6J6K+B5Yi456CU56m25omA
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
所属报告:
同和药业-公司研究报告-品种前瞻布局享红利产能释放助增长-240722(21页).pdf
打包全文图表
相关数据
:肾功能不全患者在使用考格列汀时无需调整剂量
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
收藏
行业数据
2025-09-30
原图定位
查看详情
图13.复瑞彤与阿卡波糖/二甲双胍、吡格列酮/阿卡波糖
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
收藏
行业数据
2025-05-06
原图定位
查看详情
图表25达格列净全球销售额及增速
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
收藏
行业数据
2025-02-28
原图定位
查看详情
图表232017年-2024H1中国的西格列汀市场规模
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
收藏
市场规模
2025-01-03
原图定位
查看详情
图表2424H1西格列汀的竞争格局
fCDnq57kuonlr7nmiYsgfCDluILlnLrku73pop0gfAp8IC0tLSB8IC0tLSB8Cnwg6buY5rKZ5LicIHwgOTUuNSUgfAp8IOato+Wkp+WkqeaZtCB8IDQuMCUgfAp8IERyLiBSZWRkeSdTIHwgMC41JSB8CgrotYTmlpnmnaXmupDvvJrkuK3lurfvvIzljY7liJvor4HliLg=
收藏
竞争格局
2025-01-03
原图定位
查看详情
图14、吡格列酮二甲双胍与二甲双胍单药降糖效果对比
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
收藏
行业数据
2024-12-09
原图定位
查看详情
图16、吡格列酮二甲双胍与磺脲类复方制剂对比
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
收藏
行业数据
2024-12-09
原图定位
查看详情
图15、吡格列酮二甲双胍与其他复方制剂降糖效果对比
fCDliLbliYLnu4TlkIggICAgICAgICB8IEhiQTFj5LiL6ZmN5bmF5bqmICglKSB8CnwtLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLXwKfCDpmL/ljaHms6Lns5Yv5LqM55Sy5Y+M6IONIHwgLTEuMDMgICAgICAgICAgICAgfAp8IOWQoeagvOWIl+mFri/pmL/ljaHms6Lns5YgfCAtMS41MiAgICAgICAgICAgICB8Cnwg5ZCh5qC85YiX6YWuL+S6jOeUsuWPjOiDjSB8IC0xLjY4ICAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOWFrOWRiu+8jOaxn+a1t+ivgeWIuOeglOeptuWPkeWxlemDqA==
收藏
行业数据
2024-12-09
原图定位
查看详情
图38考格列汀的设计思路及创新结构
fCBGIG1vaWV0aWVzIHwgRFBQLTTljZXlkajliLbliYIgfCDogIPmoLzliJfmsYAgKEhTSzc2NTMsIOWPjOWRqOWItuWJgikgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgQ0bigoMgICAgICAgIHwgICAgICAgICAgICAgICAgfCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5Zu96ZmF57OW5bC/55eFIGRpYWJldGVz77yM5Y2O6KW/6K+B5Yi456CU56m25omA
收藏
行业数据
2024-08-22
原图定位
查看详情
恩格列净历年销售额(亿美金)
fCDlubTku70gfCDplIDllK7pop3vvIjkur/nvo7ph5HvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18CnwgMjAxNyB8IDE1Ljk2ICAgICAgICAgIHwKfCAyMDE4IHwgMjMuODAgICAgICAgICAgfAp8IDIwMTkgfCAzMy40OSAgICAgICAgICB8CnwgMjAyMCB8IDM5Ljk5ICAgICAgICAgIHwKfCAyMDIxIHwgNjEuMzkgICAgICAgICAgfAp8IDIwMjIgfCA4Mi4wNiAgICAgICAgICB8CnwgMjAyMyB8IDEwNi4xMiAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOWFrOWRiu+8jEJJ77yM5Lit5L+h5bu65oqV6K+B5Yi4
收藏
其它
2024-06-17
原图定位
查看详情
图10.各厂商对西他列汀合成的国内相关专利布局占比
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
收藏
其它
2024-02-29
原图定位
查看详情
复瑞彤与阿卡波糖/二甲双胍、吡格列酮/阿卡波
fCDoja/niakgICAgICAgfCBIYkExY+S4i+mZjeW5heW6piAoJSkgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwKfCDpmL/ljaHms6Lns5Yv5LqM55Sy5Y+M6IONIHwgLTEuMDMgICAgICAgICAgICB8Cnwg5ZCh5qC85YiX6YWuL+mYv+WNoeazouezliB8IC0xLjUyICAgICAgICAgICAgfAp8IOWQoeagvOWIl+mFri/kuoznlLLlj4zog40gfCAtMS42OCAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOaLm+iCoeS5pu+8jOS4nOWQtOivgeWIuOeglOeptuaJgA==
收藏
其它
2024-02-01
原图定位
查看详情
GLP-1RA(口服、注射剂)与西格列汀分子类型及常见不良反应的比较
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
收藏
其它
2023-12-15
原图定位
查看详情
2022年分季度西格列他钠销售情况及环比增速(万元,%)
fCDliIblraPluqYgfCDopb/moLzliJfku5bpkqDniYfvvIjkuIflhYPvvIkgfCDnjq/mr5TvvIgl77yJIHwKfC0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLXwKfCAyMVE0ICAgfCAzICAgICAgICAgICAgICB8IC0gICAgICAgIHwKfCAyMlExICAgfCAyICAgICAgICAgICAgICB8IC0zMy4zICAgIHwKfCAyMlEyICAgfCAxNyAgICAgICAgICAgICB8IDc1MC4wICAgIHwKfCAyMlEzICAgfCA0MSAgICAgICAgICAgICB8IDE0MS4yICAgIHwKfCAyMlE0ICAgfCA3MiAgICAgICAgICAgICB8IDc1LjYgICAgIHwKCui1hOaWmeadpea6kO+8muexs+WGhee9ke+8jOW+t+mCpueglOeptuaJgA==
收藏
其它
2023-12-04
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
3)维格列汀,待新产能投产后有望进一步放量。由瑞士诺华制药有限公司研发,是继西他列汀后的又一口服给药的二肽基肽酶-IV(DPP-IV)抑制剂, 2007 年 9 月获准在欧盟上市。维格列汀是二肽基肽酶抑制剂的一个代表药物,维格列汀口服常释剂型更是成为了首个被纳入集采的 DPP-4 抑制剂类降糖药。维格列汀为高选择性 DPP-4 酶抑制剂,与其他口服降糖药相比具有降糖效果相当,但低血糖风险显著较低,且不增加患者体重的优势,市场认可度较高。目前维格列汀在中国、欧洲等重要国家或地区的专利已到期。根据药融云,2022 年诺华的维格列汀销售收入约 8.59 亿美元。
其它
原图定位
当前图表所属:
同和药业-公司研究报告-品种前瞻布局享红利产能释放助增长-240722(21页).pdf
图表92014-2028E全球面临专利到期药品销售额(亿美元)
图表82019至2023公司分地区毛利率情况
图表72019至2023公司分地区收入情况(百万元)
图表62019至1Q24公司毛利率与净利率情况
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》